Frontiers in Pharmacology, 2019 Imatinib is a first-line drug for the treatment of gastrointestinal stromal tumors (GIST). This study aims to investigate the influence of different kinds of protein concentrations and genetic polymorphisms of metabolizing enzymes and drug transporters ...
Yi Qian +9 more
doaj +1 more source
A rare case of melanosis of the hard palate mucosa in a patient with chronic myeloid leukemia [PDF]
, 2015 Imatinib Mesylate, also known as Gleevec or ST1-571, is a tyrosine-kinase inhibitor used as the gold standard medication for the chronic myeloid leukemia (CML); Imatinib has indeed deeply revolutionized the CML therapy allowing most patients to have a ...
Bosco, Daniela +4 more
core +3 more sources
Real-World Outcomes With Low-Dose Dasatinib (50 mg) in Imatinib-Resistant Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Analysis of Efficacy and Safety. [PDF]
Cancer Rep (Hoboken)ABSTRACT Background Dasatinib, a potent second‐generation tyrosine kinase inhibitor (TKI), is highly effective in chronic myeloid leukemia in chronic phase (CML‐CP) resistant to imatinib at standard dosing (100 mg daily), but is often limited by adverse events.
Gangadaran N +9 more
europepmc +2 more sources
Management of imatinib-resistant CML patients [PDF]
, 2007 Imatinib has had marked impact on outcomes in chronic myelogenous leukemia (CML) patients for all stages of the disease and is endorsed by international treatment guidelines as the first line option.
Branford S +21 more
core +1 more source
Optimized Treatment Schedules for Chronic Myeloid Leukemia [PDF]
, 2016 Over the past decade, several targeted therapies (e.g. imatinib, dasatinib, nilotinib) have been developed to treat Chronic Myeloid Leukemia (CML). Despite an initial response to therapy, drug resistance remains a problem for some CML patients.
Dingli, David +4 more
core +7 more sources
Journal of Medical Case Reports, 2011 Introduction Adjuvant imatinib improves recurrence-free survival of patients following resection of primary KIT-positive gastrointestinal stromal tumors.
Kang Yoon-Koo
doaj +1 more source
Heterogeneity of Metabolic Vulnerability in Imatinib-Resistant Gastrointestinal Stromal Tumor
Cells, 2020 Metabolic reprogramming is a hallmark of cancer cells in response to targeted therapy. Decreased glycolytic activity with enhanced mitochondrial respiration secondary to imatinib has been shown in imatinib-sensitive gastrointestional stromal tumors (GIST)
Wen-Kuan Huang +10 more
doaj +1 more source
Safe discontinuation of nilotinib in a patient with chronic myeloid leukemia: a case report [PDF]
, 2014 Case presentation. We report the case of a 64-year-old Caucasian man diagnosed with chronic-phase chronic myeloid leukemia in April 2005. After 4 years of treatment with imatinib, he became intolerant to the drug and was switched to nilotinib.
CAOCCI, GIOVANNI +2 more
core +2 more sources
The effects of time valuation in cancer optimal therapies: a study of chronic myeloid leukemia [PDF]
, 2019 Background The mathematical design of optimal therapies to fight cancer is an important research field in today’s Biomathematics and Biomedicine given its relevance to formulate patient-specific treatments. Until now, however, cancer optimal therapies
Gutiérrez Díez, Pedro José
core +2 more sources
Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells.
PLoS ONE, 2011 Challenges today concern chronic myeloid leukemia (CML) patients resistant to imatinib. There is growing evidence that imatinib-resistant leukemic cells present abnormal glucose metabolism but the impact on mitochondria has been neglected. Our work aimed
Jérome Kluza +14 more
doaj +1 more source